Askari: Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology Series)

It is now well established that pathologic thrombosis plays a central role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Born out of the understanding of the integral role of thrombus formation across the spectrum of cardiovascular diseases is the burgeoning field of antithrombotic therapies. Rigorous investigation of individual or various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, the thienopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors) has lead to a marked improvement in outcomes for patients with a thrombotic event. Nevertheless, a substantial morbidity and mortality remains associated with these thrombotic events. This realization has fueled the rapid expansion of the available armamentarium to combat pathologic thrombosis.

Antithrombotic Drug Therapy in Cardiovascular Disease will serve as a resource for individuals charged with caring for patients across the spectrum of cardiovascular diseases. This text is a comprehensive, up-to-date overview of the pathophysiology, including the genetics, of arterial and venous thrombosis followed by detailed overviews of the use of antithrombotic therapies for managing patients with various thrombotic disorders. Antithrombotic Drug Therapy in Cardiovascular Disease, a compilation of work by thought leaders in the field, is broken down into seven parts which will provide rapid access to various therapies used for each of the major classes of thrombotic disorders commonly encountered by clinicians.
The first part of Antithrombotic Drug Therapy in Cardiovascular Disease is comprised of four chapters that will provide a comprehensive overview of the basic principles of thrombosis. Chapters 1 and 2 review the key components of thrombosis, the platelet and the coagulation cascade, respectively. Chapter 3 then develops the link between inflammation, a process demonstrated to be involved in atherogenesis, and thrombosis. Chapter 4 then provides a comprehensive view of the genetics of thrombosis.
Parts II–IV then provide data and clinical recommendations for the use of antithrombotic therapies for common atherothrombotic disorders including stable coronary artery disease (Part II, Chaps. 5 and 6), non-ST-segment elevation (NSTE) ACS (Part III, Chaps. 7–10), and ST-segment elevation myocardial infarction (STEMI) (Part IV, Chaps. 11–13).
Part V provides data and recommendation for the use of various antithrombotic therapies as adjuncts to interventional procedures. Chapter 14 focuses on the use of antithrombotic therapies for PCI, while Chapter 15’s focus is on carotid and peripheral interventions. Chapter 16 will provide a detailed review of monitoring of the various antithrombotic therapies in the peri-interventional period.
Part VI focuses on venous thromboembolic diseases. This part of Antithrombotic Drug Therapy in Cardiovascular Disease will provide the data necessary to manage patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) in an evidence-based fashion. Chapter 17 focuses on prophylaxis and treatment for patients with DVT/PE. Chapter 18 synthesizes the data on the use of fibrinolysis for PE. Chapter 19 completes the section with a detailed, yet concise overview of the recommended durations of therapy for patients with venous thromboembolic diseases.
The final part of Antithrombotic Drug Therapy in Cardiovascular Disease provides detailed overviews of the use of antithrombotic therapies in several clinical conditions commonly encountered in the field of cardiology including atrial fibrillation (Chap. 20), valvular heart disease (Chap. 21), and cardiomyopathy (Chap. 22). Chapter 23 focuses on the pathophysiology and management of heparininduced thrombocytopenia. Finally, an analysis of the increasingly encountered scenario of aspirin and clopidogrel resistance will be addressed in Chapter 24.
In summary, this textbook will provide detailed, up-to-date data regarding the use of the currently available antithrombotic therapies for commonly encountered clinical situations in cardiology.

Contents
Part I Basic Principles
1 Platelets in Arterial Thrombosis
2 The Role of Coagulation in Arterial and Venous Thrombosis
3 The Link Between Inflammation and Thrombosis
4 The Genetics of Thrombosis
Part II Antithrombotic Therapy for Stable Coronary Atherosclerotic Disease 
5 Aspirin in Primary and Secondary Prevention of Cardiovascular Disease
6 Thienopyridines in Stable Coronary Disease
Part III Antithrombotic Therapy for NSTE ACS
7 Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction
8 Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
9 Direct Thrombin Inhibitors in Acute Coronary Syndromes
10 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes
Part IV Antithrombotic Therapy for STEMI
11 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines,
and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction
12 Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction
13 Fibrinolysis and Facilitated PCI
Part V Antithrombotic Therapy in Interventional Cardiology
14 Antithrombotic Therapy in Percutaneous Coronary Intervention
15 Antithrombotic Therapy in Carotid and Peripheral Intervention
16 Monitoring of Antithrombotic Therapies in Interventional Cardiology
Part VI Antithrombotic Therapy in Venous Thromboembolism
17 Venous Thromboembolism
18 Fibrinolysis for Pulmonary Embolism
19 Duration of Anticoagulant Therapy After Venous Thromboembolism
Part VII Clinical Consideration
20 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion
21 Antithrombotic Therapy for Valvular Heart Disease
22 Antithrombotic Therapy in Heart Failure and Cardiomyopathy
23 Heparin-Induced Thrombocytopenia
24 Resistance to Antiplatelet Drugs
Index

Book Details

• Hardcover: 888 pages
• Publisher: Humana Press; 1st edition (November 18, 2009)
• Language: English
• ISBN-10: 1603272348
• ISBN-13: 978-1603272346
• Product Dimensions: 10.3 x 7.6 x 1.3 inches

List Price: $269.00